Author

Bjørn Tore Gjertsen

Professor of Hematology, University of Bergen - Cited by 13,945 - Leukemia - cell signaling - clinical trials - single cell immune profiling

Biography

Bjørn Tore Gjertsen have major research interest is in development of targeted therapy and accompanying diagnostics in the aggressive blood cancer acute myeloid leukemia. His laboratory is working on intracellular signal transduction and its regulation of the tumor suppressor protein p53.
Title
Cited by
Year
Implementing a functional precision medicine tumor board for acute myeloid leukemia
D Malani, A Kumar, O Brück, M Kontro, B Yadav, M Hellesøy, ...Cancer Discovery 12 (2), 388-401, 2022202
49
2022
Moxetumomab pasudotox in heavily pre-treated patients with relapsed/refractory hairy cell leukemia (HCL): long-term follow-up from the pivotal trial
RJ Kreitman, C Dearden, PL Zinzani, J Delgado, T Robak, PD le Coutre, ...Journal of hematology & oncology 14 (1), 1-11, 2021202
39
2021
Addition of lenalidomide to intensive treatment in younger and middle-aged adults with newly diagnosed AML: the HOVON-SAKK-132 trial
Addition of lenalidomide to intensive treatment in younger and middle-aged adults with newly diagnosed AML: the HOVON-SAKK-1 trialB Löwenberg, T Pabst, J Maertens, P Gradowska, BJ Biemond, O Spertini, ...Blood advances 5 (4), 1110-1121, 2021202
32
2021
Thrombosis and thrombocytopenia after HPV vaccination
S Johansen, IJ Lægreid, SL Ernstsen, NA Azrakhsh, AO Kittang, R Lindås, ...Journal of Thrombosis and Haemostasis 20 (3), 700-704, 2022202
23
2022
Cerebrospinal fluid proteome shows disrupted neuronal development in multiple sclerosis
EF Mosleth, CA Vedeler, KH Liland, A McLeod, GH Bringeland, ...Scientific Reports (1), 4087, 2021202
11
2021
Overlapping features of therapy-related and de novo NPM1-mutated AML
J Othman, M Meggendorfer, E Tiacci, C Thiede, R Schlenk, R Dillon, ...Blood, The Journal of the American Society of Hematology 141 (15), 1846-1857, 2023202
9
2023
Repurposing chlorpromazine for anti-leukaemic therapy by nanoparticle encapsulation
ET Gundersen, JL Førde, BS Tislevoll, C Leitch, G Barratt, BT Gjertsen, ...International journal of pharmaceutics 612, 12126, 2022202
9
2022
Inferior outcome of addition of the aminopeptidase inhibitor tosedostat to standard intensive treatment for elderly patients with aml and high risk mds
J Janssen, B Löwenberg, M Manz, M Bargetzi, B Biemond, P Borne, ...Cancers 13 (4), 672, 2021202
9
2021
Colony stimulating factor 1 receptor in acute myeloid leukemia
KY Sletta, O Castells, BT GjertsenFrontiers in oncology 11, 654817, 2021202
9
2021
Liquid biopsies in solid cancers: implementation in a nordic healthcare system
O Nordgård, R Brendsdal Forthun, M Lapin, BH Grønberg, KH Kalland, ...Cancers 13 (8), 1861, 2021202
7
2021
Systemic and local innate immune responses to surgical co-transplantation of mesenchymal stromal cells and biphasic calcium phosphate for bone regeneration
N Rana, S Suliman, S Mohamed-Ahmed, S Gavasso, BT Gjertsen, ...Acta Biomaterialia 141, 440-453, 2022202
7
2022
Sex disparity in acute myeloid leukaemia with FLT3 internal tandem duplication mutations: implications for prognosis
M Hellesøy, C Engen, T Grob, B Löwenberg, PJM Valk, BT GjertsenMolecular Oncology 15 (9), 2285-2299, 2021202
7
2021
Temperature-dependent autoactivation associated with clinical variability of PDGFRB Asn666 substitutions
Temperature-dependent autoactivation associated with clinical variability of PDGFRB Asn substitutionsC Bredrup, I Cristea, LA Safieh, E Di Maria, BT Gjertsen, KS Tveit, F Thu, ...Human molecular genetics 30 (1), 72-77, 2021202
6
2021
Phenotypic characterization by mass cytometry of the microenvironment in ovarian cancer and impact of tumor dissociation methods
S Anandan, LCV Thomsen, SE Gullaksen, T Abdelaal, K Kleinmanns, ...Cancers 13 (4), 755, 2021202
6
2021
A national precision cancer medicine implementation initiative for Norway
K Taskén, HEG Russnes, E Aas, L Bjørge, ES Blix, E Enerly, GL Fagereng, ...Nature Medicine 28 (), 88-887, 2022202
5
2022
Bimodal expression of potential drug target CLL‐1 (CLEC12A) on CD34+ blasts of AML patients
LL Ngai, CY Ma, O Maguire, AD Do, A Robert, AC Logan, EA Griffiths, ...European Journal of Haematology 107 (3), 343-33, 2021202
5
2021
p53 protein isoform profiles in AML: correlation with distinct differentiation stages and response to epigenetic differentiation therapy
I Haaland, SM Hjelle, H Reikvam, A Sulen, A Ryningen, E McCormack, ...Cells 10 (), 833, 2021202
4
2021
FLT3‐ITD mutations in acute myeloid leukaemia–molecular characteristics, distribution and numerical variation
C Engen, M Hellesøy, T Grob, A Al Hinai, A Brendehaug, L Wergeland, ...Molecular Oncology 15 (9), 2300-2317, 2021202
4
2021
Long‐term tolerability and efficacy after initial PegIFN‐α addition to dasatinib in CML‐CP: Five‐year follow‐up of the NordCML007 study
H Flygt, S Söderlund, J Stentoft, J Richter, P Koskenvesa, S Mustjoki, ...European journal of haematology 107 (6), 617-623, 2021202
4
2021
Improving public cancer care by implementing precision medicine in Norway: IMPRESS-Norway
Å Helland, HG Russnes, GL Fagereng, K Al-Shibli, Y Andersson, T Berg, ...Journal of translational medicine 20 (1), 1-11, 2022202
3
2022

Referred From: https://scholar.google.com/citations?user=cCu0is8AAAAJ&hl=en&oi=sra

Cited by
Citations 13945
h-index 63
i10-index 196
Recommended Journals
Open Access Journals